

---

NHSEED - - Economic Study or Review

## Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients

**Code:**  
NHSEED-22013051422    **Year:** 2013    **Date:** 2013

**Author:** Cies JJ

### Study design (if review, criteria of inclusion for studies)

retrospective cohort study

### Participants

40 CF patients

### Interventions

Managed therapeutic drug monitoring (TDM) by clinical pharmacist (CP) compared with usual care (UC).

### Outcome measures

Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients. Number of pediatric CF patients achieving Aminoglycoside (AG) pharmacokinetic and pharmacodynamic (PK/PD) targets when a clinical pharmacist (CP) managed therapeutic drug monitoring (TDM) compared with usual care (UC).

### Main results

Twenty-nine patients with 52 courses of AGs were included the CP group, and 22 patients with 42 courses were included the UC group. Ninety-eight percent of patients in the CP group reached AG PK/PD targets compared with 71% in the UC group,  $P=0.001$ .

### Authors' conclusions

CP managed TDM resulted in a significantly higher percentage of pediatric CF patients achieving AG PK/PD targets 3 days sooner with an average LOS that was 3 days shorter. CP managed TDM resulted in significantly fewer dosage adjustments, drug levels, and cost associated with serum sampling, drug wastage, and LOS.

<http://onlinelibrary.wiley.com/doi/10.1002/ppul.22745/abstract>

### See also

Pediatr Pulmonol. 2012 Dec 31. doi: 10.1002/ppul.22745.

### Keywords

Anti-Bacterial Agents; non pharmacological intervention - psycho-soc-edu-org; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection; Organization; Aminoglycosides;